Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

From Inflammation Biomarkers to Remoddeling (FAPI PET/CT) Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19

NCT06911476 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT06911476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06911476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
From Inflammation Biomarkers to Remoddeling (FAPI PET/CT) Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19
Lead sponsor
University Medical Center Groningen
Phase
Observational
Overall status
Not yet recruiting
Start date
May 31, 2025
Completion date
December 31, 2025
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

fap, fapi, fibroblast, fibroblast activation protein inhibitor, long covid, long covid-19, pasc, pasc post acute sequelae of covid 19, restrictive lung disease